Share 'Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy'
New release from Prosensa:
£10m in milestone payments received from GlaxoSmithKline
Leiden, The Netherlands, 23 October 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this